AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19191893 — intervention group
Group type: COMPARATOR
Intervention: PAM7 (7 days)
Number of subjects: 592
Study 19191893 — intervention group
Group type: EXPERIMENTAL
Intervention: PACl (clarithromycin)
Number of subjects: 592
Study 19191893 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM (metronidazole)
Number of subjects: 592
Study 16510864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) exercise
Number of subjects: 311
Study 16510864 — intervention group
Group type: COMPARATOR
Intervention: Wellness education (WE)
Number of subjects: 311
Study 14640239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron dextran (IVFe) infusion to achieve target serum ferritin concentrations of 200 ng/ml
Number of subjects: 0
Study 14640239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron dextran (IVFe) infusion to achieve target serum ferritin concentrations of 400 ng/ml
Number of subjects: 0
Study 10850936 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln mixture (3 g HMB, 14 g L-glutamine, and 14 g L-arginine given in two divided doses daily for 8 weeks)
Number of subjects: 68
Study 10850936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 68
Study 10850936 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln mixture
Number of subjects: 68
Study 10850936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9062567 — intervention group
Group type: EXPERIMENTAL
Intervention: Casting combined with stretching
Number of subjects: 9
Study 9062567 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 9
Study 8450520 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental calcium (2 g) for 12 weeks
Number of subjects: 20
Study 8450520 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 20
Study 3532297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at night)
Number of subjects: 205
Study 3532297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at night)
Number of subjects: 205
Study 3532297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg at night)
Number of subjects: 205
Study 3532297 — intervention group
Group type: COMPARATOR
Intervention: Antacids (as needed for symptomatic relief)
Number of subjects: 205
Study 30368033 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based micronutrient supplement with loyalty cards
Number of subjects: 0
Study 30368033 — intervention group
Group type: COMPARATOR
Intervention: Food-based micronutrient supplement with price discounts
Number of subjects: 0
Study 30368033 — intervention group
Group type: COMPARATOR
Intervention: Retail distribution of micronutrient supplements
Number of subjects: 0
Study 27393520 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg oral conjugated equine estrogens (CEE)
Number of subjects: 100
Study 27393520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 (50 μg/d) with micronized P (200 mg daily)
Number of subjects: 100
Study 27393520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27393520 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including CEE, E2, and placebo)
Number of subjects: 100
Study 27393520 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 100
Study 25027615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide (DM) syrup, age-weight dosing schedule (DM range 7.5-24.75 mg for Groups A and B; 30 mg for Group C)
Number of subjects: 38
Study 25027615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide (DM) syrup
Number of subjects: 38
Study 22419715 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist stimulation (buserelin 100 μg, s.c.) during hyperinsulinemic clamp (80 mU/m2 · min)
Number of subjects: 9
Study 22419715 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist stimulation (buserelin 100 μg, s.c.) during saline infusion
Number of subjects: 9
Study 22419715 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist stimulation (buserelin 100 μg, s.c.) during both hyperinsulinemia and saline infusion
Number of subjects: 9
Study 20166410 — intervention group
Group type: EXPERIMENTAL
Intervention: High value composite (GHV)
Number of subjects: 65
Study 20166410 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium value composite (GMV)
Number of subjects: 65
Study 20166410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low value composite (GLV)
Number of subjects: 65
Study 20166410 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 65
Study 18616643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg tablet twice daily for 24 weeks
Number of subjects: 50
Study 18616643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18616643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg tablet
Number of subjects: 50
Study 16088104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate at 32 mmol/l (modality A)
Number of subjects: 27
Study 16088104 — intervention group
Group type: COMPARATOR
Intervention: Dialysate bicarbonate at 26 mmol/l (modality B)
Number of subjects: 27
Study 16088104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate calcium at 1.50 mmol/l (modality C)
Number of subjects: 27
Study 16088104 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of modality A with ACE inhibitors or angiotensin II blockers
Number of subjects: 27
Study 16088104 — intervention group
Group type: COMPARATOR
Intervention: Comparison between modalities A and B
Number of subjects: 27
Study 12205647 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (5mg)
Number of subjects: 12
Study 12205647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10613449 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBP) 200 mg/m2/day continuous infusion (days 3 to 7) with idarubicin (IDA) 12 mg/m2/day i.v. bolus (days 1 to 3)
Number of subjects: 53
Study 10613449 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBP) 200 mg/m2/day continuous infusion (days 3 to 7) with mitoxantrone (MIT) 12 mg/m2/day i.v. bolus (days 1 to 3)
Number of subjects: 53
Study 10613449 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBP) with idarubicin (IDA)
Number of subjects: 53
Study 10613449 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBP) with mitoxantrone (MIT)
Number of subjects: 53
Study 8526957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg mivacurium (2 x ED95)
Number of subjects: 48
Study 8526957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015 mg/kg mivacurium (20% of ED95) followed by 0.07 mg/kg mivacurium (ED95)
Number of subjects: 48
Study 8526957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.46 mg/kg atracurium (2 x ED95)
Number of subjects: 48
Study 8526957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.046 mg/kg atracurium (20% of ED95) followed by 0.23 mg/kg atracurium (ED95)
Number of subjects: 48
Study 1835110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium 0.5 mg and fenoterol 1.25 mg
Number of subjects: 20
Study 1835110 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study 7124560 — intervention group
Group type: EXPERIMENTAL
Intervention: Students attached to geriatric firms
Number of subjects: 0
Study 7124560 — intervention group
Group type: COMPARATOR
Intervention: Students attached to general medical firms
Number of subjects: 0
Study 29699472 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence training program (3 weeks)
Number of subjects: 59
Study 29699472 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence training
Number of subjects: 59
Study 29699472 — intervention group
Group type: COMPARATOR
Intervention: Placebo control training program
Number of subjects: 59
Study 28952166 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 64
Study 28952166 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 64
Study 28952166 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Haloperidol and Olanzapine)
Number of subjects: 64
Study 25872457 — intervention group
Group type: EXPERIMENTAL
Intervention: DEM-DISC (accessed for 12 months)
Number of subjects: 73
Study 25872457 — intervention group
Group type: EXPERIMENTAL
Intervention: DEM-DISC (frequent access)
Number of subjects: 73
Study 25872457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to DEM-DISC)
Number of subjects: 73
Study 23627719 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning among larger groups (many competitors)
Number of subjects: 0
Study 23627719 — intervention group
Group type: COMPARATOR
Intervention: Winning among smaller groups (few competitors)
Number of subjects: 0
Study 23627719 — intervention group
Group type: EXPERIMENTAL
Intervention: False feedback of placing in the top 10% in a creativity challenge among many competitors
Number of subjects: 0
Study 23627719 — intervention group
Group type: COMPARATOR
Intervention: False feedback of placing in the top 10% in a creativity challenge among few competitors
Number of subjects: 0
Study 21159220 — intervention group
Group type: EXPERIMENTAL
Intervention: Food opportunities during the school day
Number of subjects: 145
Study 19587123 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (CRD) for 6 weeks
Number of subjects: 39
Study 19587123 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (CRD) continued for an additional 6 weeks
Number of subjects: 39
Study 19587123 — intervention group
Group type: COMPARATOR
Intervention: AHA diet (55% carbohydrate, 25-30% fat, 15-20% protein) for 6 weeks
Number of subjects: 39
Study 18021533 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 542
Study 18021533 — intervention group
Group type: COMPARATOR
Intervention: Control (non-antiviral interventions)
Number of subjects: 542
Study 16330292 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 puffs of oral insulin spray
Number of subjects: 6
Study 16330292 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 puffs of oral insulin spray
Number of subjects: 6
Study 16330292 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 puffs of oral insulin spray
Number of subjects: 6
Study 16330292 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneously injected regular insulin (0.1 U/kg SC)
Number of subjects: 6
Study 16330292 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 6
Study 11907619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber pacing
Number of subjects: 0
Study 11907619 — intervention group
Group type: COMPARATOR
Intervention: Single chamber ventricular pacing
Number of subjects: 0
Study 9558132 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin administered 5 hours before DLMO
Number of subjects: 0
Study 9558132 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary DLMO concentration
Number of subjects: 0
Study 7892486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-triggered helical CT
Number of subjects: 30
Study 7892486 — intervention group
Group type: COMPARATOR
Intervention: Conventional contrast material‐enhanced helical CT
Number of subjects: 30
Study 1975893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 9 and 3 month courses of cyclophosphamide and prednisolone
Number of subjects: 58
Study 1975893 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 58
Study 707354 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified diet with sodium restriction
Number of subjects: 20
Study 707354 — intervention group
Group type: COMPARATOR
Intervention: Traditional sodium-fluid restricted diet
Number of subjects: 20
Study 31531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic treatment regimes (DTRs) for chronic periodontitis
Number of subjects: 0
Study 31531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment sharing
Number of subjects: 0
Study 31531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis plan and sample size calculation method
Number of subjects: 0
Study 31531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation studies
Number of subjects: 0
Study 31111879 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM
Number of subjects: 919
Study 31111879 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 919
Study 28427459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (12-week duration)
Number of subjects: 170
Study 26270200 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 70
Study 26270200 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 70
Study 26270200 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 70
Study 24369765 — intervention group
Group type: COMPARATOR
Intervention: Low calorie dietary advice + placebo (1 g olive oil)
Number of subjects: 118
Study 24369765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie dietary advice emphasising fish + placebo
Number of subjects: 118
Study 24369765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie dietary advice emphasising fish diet + LCn3PUFA supplements
Number of subjects: 118
Study 21366361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 3900 mg single dose
Number of subjects: 55
Study 21366361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 1800-3900 mg/day for 7 days
Number of subjects: 55
Study 21366361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 21366361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (all doses)
Number of subjects: 55
Study 19673746 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 50
Study 19673746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17936509 — intervention group
Group type: EXPERIMENTAL
Intervention: LLT intervention group
Number of subjects: 65
Study 17936509 — intervention group
Group type: COMPARATOR
Intervention: FASD control group (FASD-C)
Number of subjects: 65
Study 17936509 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed control group (NONEXP-C)
Number of subjects: 65
Study 15585428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical message (use male condoms; if not, use female condoms; if not, use spermicide)
Number of subjects: 112
Study 15585428 — intervention group
Group type: COMPARATOR
Intervention: Male-condom-only message (use male condoms)
Number of subjects: 112
Study 15585428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical message
Number of subjects: 112
Study 11743900 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sustained-release theophylline preparation twice daily for 4 weeks
Number of subjects: 19
Study 9210705 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ detection of HCV in liver tissue using a combination of nonradioactive in situ hybridization and immunohistochemistry.
Number of subjects: 10
Study 9210705 — intervention group
Group type: COMPARATOR
Intervention: Control group (HCV negative HCC patients and one patient with epithelioid hemangioendothelioma).
Number of subjects: 10
Study 7950222 — intervention group
Group type: EXPERIMENTAL
Intervention: Geng‐Nian‐Shu (GNS) treatment
Number of subjects: 370
Study 7950222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 7950222 — intervention group
Group type: EXPERIMENTAL
Intervention: Geng‐Nian‐Shu (GNS) treatment in ovariectomized white rats
Number of subjects: 370
Study 31595459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol sedation
Number of subjects: 55
Study 29654019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine of DKK250 (€34) for non-attendance
Number of subjects: 6746
Study 29654019 — intervention group
Group type: COMPARATOR
Intervention: No fine policy
Number of subjects: 6746
Study 29654019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine policy
Number of subjects: 6746
Study 28806908 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT OUT - providing all smokers with tobacco-cessation treatment unless they refuse it
Number of subjects: 1000
Study 28806908 — intervention group
Group type: COMPARATOR
Intervention: OPT IN - current practice of screening for readiness and only offering treatment to smokers who say they are ready to quit
Number of subjects: 1000
Study 25656169 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 16492
Study 25656169 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16492
Study 23021943 — intervention group
Group type: EXPERIMENTAL
Intervention: MTCT prophylaxis
Number of subjects: 35
Study 21105351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinuforte (INVAR, Russia)
Number of subjects: 0
Study 18705917 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 64 mmol/day (16 g/day)
Number of subjects: 1200
Study 18705917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 16872900 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch Off‐Get Active intervention
Number of subjects: 312
Study 12826550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with 0.5 microg x mL(-1) sufentanil (Group R+S0.5)
Number of subjects: 32
Study 12826550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with 0.75 microg x mL(-1) sufentanil (Group R+S0.75)
Number of subjects: 32
Study 12826550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with 1 microg x mL(-1) sufentanil (Group R+S1)
Number of subjects: 32
Study 12826550 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 32
Study 10997375 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula + LCP
Number of subjects: 3
Study 10997375 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Milk
Number of subjects: 3
Study 10997375 — intervention group
Group type: COMPARATOR
Intervention: Formula
Number of subjects: 3
Study 8782501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (50 ml of 40 percent ethanol)
Number of subjects: 36
Study 8782501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isocaloric placebo with the aroma of rum)
Number of subjects: 36
Study 1600777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 39
Study 1600777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 6142034 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 0
Study 6142034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 0
Study 6142034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31229326 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Number of subjects: 77
Study 31229326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 29655114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy and antidepressants (sertraline and mianserin)
Number of subjects: 0
Study 29655114 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27314465 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-based neural network model (suicide risk assessment tool)
Number of subjects: 429
Study 24924278 — intervention group
Group type: EXPERIMENTAL
Intervention: Target contact lens power for distance
Number of subjects: 34
Study 24924278 — intervention group
Group type: COMPARATOR
Intervention: 30 D contact lens
Number of subjects: 34
Study 24924278 — intervention group
Group type: COMPARATOR
Intervention: Regression-estimated contact lens power
Number of subjects: 34
Study 24924278 — intervention group
Group type: COMPARATOR
Intervention: SRK/T-estimated power
Number of subjects: 34
Study 22385940 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital delay less than 1 day
Number of subjects: 1023
Study 22385940 — intervention group
Group type: COMPARATOR
Intervention: Prehospital delay
Number of subjects: 1023
Study 20410617 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 239
Study 20410617 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood aggregometer
Number of subjects: 239
Study 19076849 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 26
Study 19076849 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing
Number of subjects: 26
Study 15983223 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 19
Study 15983223 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study 12732833 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid solution G
Number of subjects: 0
Study 12732833 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid solution R
Number of subjects: 0
Study 12732833 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 11048353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) plus disulfiram
Number of subjects: 96
Study 11048353 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step facilitation (TSF) plus disulfiram
Number of subjects: 96
Study 11048353 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management (CM) plus disulfiram
Number of subjects: 96
Study 11048353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) without disulfiram
Number of subjects: 96
Study 11048353 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step facilitation (TSF) without disulfiram
Number of subjects: 96
Study 11048353 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (in combination with any treatment)
Number of subjects: 96
Study 11048353 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of abstinence during treatment
Number of subjects: 96
Study 8622066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsacrine (100 mg/m2/d on days 1 to 5) and Etoposide (200 mg/m2/d on days 1 to 3)
Number of subjects: 167